No FDA panel bodes well for Pfizer's palbociclib
This article was originally published in Scrip
Executive Summary
Shares of Pfizer got about a 2.5% boost on 8 January after the company disclosed the FDA currently has no plans to convene its Oncologic Drugs Advisory Committee (ODAC) to scrutinize the new drug application (NDA) for palbociclib – news that had some on Wall Street speculating the pharma giant could win an earlier-than-expected approval of the experimental breast cancer medicine.